• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms.

作者信息

Chen Jiang, Duda Dan G

机构信息

Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom St, Cox-734, Boston, MA 02114, USA; Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou 310016, China.

Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom St, Cox-734, Boston, MA 02114, USA.

出版信息

EBioMedicine. 2020 Feb;52:102644. doi: 10.1016/j.ebiom.2020.102644. Epub 2020 Jan 31.

DOI:10.1016/j.ebiom.2020.102644
PMID:32014823
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6997488/
Abstract
摘要

相似文献

1
Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms.克服肝细胞癌中索拉非尼治疗耐药性：在治疗模式迅速变化之际的未来展望。
EBioMedicine. 2020 Feb;52:102644. doi: 10.1016/j.ebiom.2020.102644. Epub 2020 Jan 31.
2
[Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].索拉非尼治疗晚期肝细胞癌的现状与未来展望
Nihon Shokakibyo Gakkai Zasshi. 2012 Aug;109(8):1346-54.
3
Hepatocellular carcinomas: evolution to sorafenib resistance through hepatic leukaemia factor.肝细胞癌：通过肝白血病因子向索拉非尼耐药演变
Gut. 2019 Oct;68(10):1728-1730. doi: 10.1136/gutjnl-2019-318999. Epub 2019 Jul 3.
4
[Experience and future prospect of hepatocellular carcinoma treatment by sorafenib].索拉非尼治疗肝细胞癌的经验与未来展望
Nihon Shokakibyo Gakkai Zasshi. 2019;116(1):18-27. doi: 10.11405/nisshoshi.116.18.
5
Reply to: "Predictors of sorafenib benefit in patients with hepatocellular carcinoma".回复：“索拉非尼对肝细胞癌患者疗效的预测因素”
J Hepatol. 2018 Mar;68(3):620-621. doi: 10.1016/j.jhep.2017.10.013. Epub 2017 Oct 24.
6
Long-term treatment of hepatocellular carcinoma with sorafenib.索拉非尼对肝细胞癌的长期治疗
Infez Med. 2013 Jun;21(2):167-8.
7
Is Sorafenib an Optimal Treatment for Hepatocellular Carcinoma With Macrovascular Invasion or Metastatic Disease?索拉非尼是伴有大血管侵犯或转移性疾病的肝细胞癌的最佳治疗方法吗？
Hepatology. 2018 Aug;68(2):786. doi: 10.1002/hep.29862.
8
Predictors of sorafenib benefit in patients with hepatocellular carcinoma.索拉非尼对肝细胞癌患者疗效的预测因素。
J Hepatol. 2018 Mar;68(3):619-620. doi: 10.1016/j.jhep.2017.09.028. Epub 2017 Oct 24.
9
Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.下调 Raf-1 激酶抑制蛋白作为肝癌细胞系对索拉非尼耐药的机制。
J Cancer Res Clin Oncol. 2018 Aug;144(8):1487-1501. doi: 10.1007/s00432-018-2672-y. Epub 2018 Jun 1.
10
Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?肝细胞癌与索拉非尼：存在过多的耐药机制？
Gut. 2013 Dec;62(12):1674-5. doi: 10.1136/gutjnl-2013-304564. Epub 2013 Mar 12.

引用本文的文献

1
Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment.Pifithrin-μ使mTOR激活的肝癌对索拉非尼治疗敏感。
Cell Death Dis. 2025 Jan 26;16(1):42. doi: 10.1038/s41419-025-07332-6.
2
Suppression of CTC1 inhibits hepatocellular carcinoma cell growth and enhances RHPS4 cytotoxicity.抑制CTC1可抑制肝癌细胞生长并增强RHPS4的细胞毒性。
Mol Biol Rep. 2024 Jul 13;51(1):799. doi: 10.1007/s11033-024-09756-3.
3
Unveiling the Potential of Extracellular Vesicles as Biomarkers and Therapeutic Nanotools for Gastrointestinal Diseases.揭示细胞外囊泡作为胃肠道疾病生物标志物和治疗纳米工具的潜力。
Pharmaceutics. 2024 Apr 21;16(4):567. doi: 10.3390/pharmaceutics16040567.
4
Engineered extracellular vesicles mediated CRISPR-induced deficiency of IQGAP1/FOXM1 reverses sorafenib resistance in HCC by suppressing cancer stem cells.工程细胞外囊泡介导的 CRISPR 诱导的 IQGAP1/FOXM1 缺陷逆转 HCC 索拉非尼耐药性，抑制肿瘤干细胞。
J Nanobiotechnology. 2023 May 18;21(1):154. doi: 10.1186/s12951-023-01902-6.
5
An autophagy-inducing stapled peptide promotes c-MET degradation and overrides adaptive resistance to sorafenib in c-MET hepatocellular carcinoma.一种诱导自噬的环肽可促进c-MET降解，并克服c-MET肝细胞癌对索拉非尼的适应性耐药。
Biochem Biophys Rep. 2022 Dec 17;33:101412. doi: 10.1016/j.bbrep.2022.101412. eCollection 2023 Mar.
6
Ginsenoside Rg3 in combination with artesunate overcomes sorafenib resistance in hepatoma cell and mouse models.人参皂苷Rg3与青蒿琥酯联合使用可克服肝癌细胞和小鼠模型中的索拉非尼耐药性。
J Ginseng Res. 2022 May;46(3):418-425. doi: 10.1016/j.jgr.2021.07.002. Epub 2021 Jul 14.
7
Hypoxia signaling: Challenges and opportunities for cancer therapy.缺氧信号转导：癌症治疗的挑战和机遇。
Semin Cancer Biol. 2022 Oct;85:185-195. doi: 10.1016/j.semcancer.2021.10.002. Epub 2021 Oct 7.
8
Messing Up the Cancer Stem Cell Chemoresistance Mechanisms Supported by Tumor Microenvironment.扰乱由肿瘤微环境支持的癌症干细胞化疗耐药机制。
Front Oncol. 2021 Jul 20;11:702642. doi: 10.3389/fonc.2021.702642. eCollection 2021.
9
NOX1 inhibition attenuates the development of a pro-tumorigenic environment in experimental hepatocellular carcinoma.NOX1 抑制可减轻实验性肝细胞癌中促肿瘤环境的发展。
J Exp Clin Cancer Res. 2021 Jan 23;40(1):40. doi: 10.1186/s13046-021-01837-6.

本文引用的文献

1
The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma.索拉非尼耐药的微环境和代谢方面。
EBioMedicine. 2020 Jan;51:102610. doi: 10.1016/j.ebiom.2019.102610. Epub 2020 Jan 6.
2
CRAF Methylation by PRMT6 Regulates Aerobic Glycolysis-Driven Hepatocarcinogenesis via ERK-Dependent PKM2 Nuclear Relocalization and Activation.PRMT6 通过 CRAF 甲基化调控 ERK 依赖的 PKM2 核转位和激活来驱动有氧糖酵解促进肝癌发生。
Hepatology. 2020 Apr;71(4):1279-1296. doi: 10.1002/hep.30923. Epub 2020 Jan 24.
3
Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond.针对肝细胞癌的靶向和免疫治疗：2019 年及以后的预测。
World J Gastroenterol. 2019 Feb 21;25(7):789-807. doi: 10.3748/wjg.v25.i7.789.
4
Molecular therapies and precision medicine for hepatocellular carcinoma.肝细胞癌的分子治疗和精准医学。
Nat Rev Clin Oncol. 2018 Oct;15(10):599-616. doi: 10.1038/s41571-018-0073-4.
5
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.利用抗血管生成药物增强癌症免疫治疗：机遇与挑战。
Nat Rev Clin Oncol. 2018 May;15(5):325-340. doi: 10.1038/nrclinonc.2018.29. Epub 2018 Mar 6.
6
Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.肿瘤相关中性粒细胞招募巨噬细胞和 T 调节细胞促进肝细胞癌进展和索拉非尼耐药。
Gastroenterology. 2016 Jun;150(7):1646-1658.e17. doi: 10.1053/j.gastro.2016.02.040. Epub 2016 Feb 26.
7
Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.索拉非尼通过基质衍生因子 1 ɑ/C-X-C 受体型 4 轴和骨髓分化抗原阳性髓样细胞浸润对肝与肿瘤纤维化的差异作用及其在小鼠中的机制。
Hepatology. 2014 Apr;59(4):1435-47. doi: 10.1002/hep.26790. Epub 2014 Feb 18.
8
Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.微环境在肝细胞癌发病机制和治疗中的作用。
Gastroenterology. 2013 Mar;144(3):512-27. doi: 10.1053/j.gastro.2013.01.002. Epub 2013 Jan 9.
9
Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.缺氧介导的索拉非尼耐药可以通过 EF24 克服，EF24 通过 Von Hippel-Lindau 肿瘤抑制因子依赖性 HIF-1α 抑制在肝细胞癌中发挥作用。
Hepatology. 2013 May;57(5):1847-57. doi: 10.1002/hep.26224. Epub 2013 Mar 14.
10
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.索拉非尼的发现与研发：一种用于治疗癌症的多激酶抑制剂
Nat Rev Drug Discov. 2006 Oct;5(10):835-44. doi: 10.1038/nrd2130.